Maternal activation of the EGFR prevents translocation of gut-residing pathogenic *Escherichia coli* in a model of late-onset neonatal sepsis

Kathryn A. Knoop\textsuperscript{a,b,*}, Paige E. Coughlin\textsuperscript{b}, Alexandria N. Floyd\textsuperscript{d}, I. MalickNdao\textsuperscript{e}, Carla Hall-Moore\textsuperscript{e}, Nurmohammad Shaikh\textsuperscript{c}, Andrew J. Gasparrini\textsuperscript{d}, Brigida Rusconi\textsuperscript{d}, Marilyn Escobedo\textsuperscript{e}, Misty Good\textsuperscript{f}, Barbara B. Warner\textsuperscript{g}, Phillip I. Tarr\textsuperscript{f}\textsuperscript{1}, and Rodney D. Newberry\textsuperscript{b}

\textsuperscript{a}Department of Immunology, Mayo Clinic, Rochester, MN 55905; \textsuperscript{b}Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110; \textsuperscript{c}Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110; \textsuperscript{d}The Edison Family Center for Genome Sciences & Systems Biology, Washington University School of Medicine, St. Louis, MO 63110; \textsuperscript{e}Department of Pediatrics, University of Oklahoma School of Medicine, Oklahoma City, OK 73109; and \textsuperscript{f}Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110

Edited by Lora V. Hooper, University of Texas Southwestern Medical Center, Dallas, TX, and approved February 5, 2020 (received for review July 23, 2019)

Late-onset sepsis (LOS) is a highly consequential complication of preterm birth and is defined by a positive blood culture obtained after 72 h of age. The causative bacteria can be found in patients’ intestinal tracts days before dissemination, and cohort studies suggest reduced LOS risk in breastfed preterm infants through unknown mechanisms. Reduced concentrations of epidermal growth factor (EGF) of maternal origin within the intestinal tract of mice correlated to the translocation of a gut-resident human pathogen *Escherichia coli*, which spreads systemically and caused a rapid, fatal disease in pups. Translocation of *Escherichia coli* was associated with the formation of colonic goblet cell-associated antigen passages (GAPs), which translocate enteric bacteria across the intestinal epithelium. Thus, maternally derived EGF, and potentially other EGF ligands, prevents dissemination of a gut-resident pathogen by inhibiting goblet cell-mediated bacterial translocation. Through manipulation of maternally derived EGF and alteration of the earliest gut defenses, we have developed an animal model of pathogen dissemination which recapitulates gut-origin neonatal LOS.

Late-onset neonatal sepsis (LOS) can be caused by a variety of pathogens, occurs at least 72 h after birth, accounts for 26% of all deaths in preterm infants, and results in an increased risk of long-term neurocognitive problems (1, 2). LOS has remained a significant challenge in preterm infant care (3) due to the continuing reduction in the age of viability of very low birth weight (VLBW, birth weight ≤ 1,500 g) infants, who are at greater risk for bloodstream infections (BSIs), with an incidence of 10% and a mortality rate between 30 to 50% (1). Recent clinical data indicate incidence of LOS may be decreasing, though it remains unclear which interventions have the most impact in reduction of neonatal BSIs and LOS (4). Great effort has been devoted to hygiene related to invasive procedures (5, 6), and there is increasing focus on breastfeeding (7, 8).

In a substantial portion of LOS cases, the causative pathogen can be found to reside in the gut before it disseminates (9–12). It is hypothesized that an immature intestinal barrier enables translocation of such resident gut bacteria, but the mechanisms allowing or inhibiting translocation of the gut microbiota in early life remain unknown. These infections occur during the first 60 d of life, a time in life when exclusive breastfeeding is recommended. Formula-fed preterm infants have greater intestinal permeability compared to breast milk-fed preterm infants (13), and in animal models, formula feeding enables bacterial translocation from the gut to the mesenteric lymph nodes (MLNs) and the liver (14–16). Epidermal growth factor (EGF) is a growth factor that is maternally supplied with high concentrations in colostrum and decreases in concentration in breast milk throughout lactation (17–19), and reduces bacterial translocation in formula-fed animals (20).

Here we disrupt EGF receptor (EGFR) signaling in neonatal mice and use asynchronously cross-fostered pups to reduce high luminal EGF concentrations originating from maternal milk perinatally, both of which result in bacterial translocation from the gut to the mesenteric lymph nodes and spleen. Following EGFR disruption or asynchronously cross-fostering, mice developed a rapid fatal response to oral challenge of *Escherichia coli* isolated from the bloodstream of LOS patients, which were also of gut origin in those neonates. However, other gut-resident commensal *E. coli* from infants without disease were not lethal, despite their ability to translocate in this model. *E. coli* translocation was associated with goblet cell-associated antigen passages (GAPs) formation by colon goblet cells and inhibited by luminal EGF via EGFR activation in goblet cells. Thus maternal...
EGF, and potentially other EGFR ligands, inhibits translocation of a gut-residing pathogen in offspring by directly acting on goblet cells and inhibiting GAP formation in the offspring’s colon, thereby interdicting gut-resident pathogens from traversing the epithelium and gaining systemic access.

Results
Infants born preterm and fed mother’s own milk (MOM) have a reduced risk of LOS (21, 22). EGF is abundant in breast milk after parturition, decreases throughout lactation, and has been observed to improve intestinal barrier function and reduce bacterial translocation in offspring (20). Therefore, we measured EGF in the stool of VLBW infants (SI Appendix, Table S1) that were fed MOM or formula over the first 60 d of life to assess the contribution of maternal breast milk to luminal EGF concentrations. Stools from the breastfed children contained significantly greater concentrations of EGF, and this concentration diminished over time, reflecting the reduction in concentration in breast milk of EGF (17–19) (Fig. L4 and SI Appendix, Fig. S1A). Similar temporal trends of EGFR ligands amphiregulin (AREG), transforming growth factor alpha (TGF-α), and heparin-binding EGF like growth factor (HB-EGF), which have been reported to be present in human breast milk (17, 23, 24), were not observed in the stool. Additionally, there were no differences in the fecal concentrations of AREG, TGF-α, and HB-EGF in the stools of MOM-fed or formula-fed children, which were overall less abundant than EGF in the stool, particularly in the first 4 wk of life (SI Appendix, Fig. S1 B–D, compare to Fig. 1A). EGF concentrations in murine milk also diminished over time, reflecting a gradient that could also be measured in the stool (SI Appendix, Fig. S2A) and lumen (25) of pups during early life, a time when neonatal mice immunologically resemble the preterm human infant gut (26, 27).

We next asked if maternal EGF induces a response in the offspring that prevents translocation of gut bacteria via activation of the EGFR. Pups were colonized with *E. coli* by oral gavage of $2 \times 10^5$ CFUs. Fig. 1. Inhibition of EGFR results in bacterial translocation of gut-residing *E. coli*. (A) Concentration of EGF as measured by ELISA from the stool of children fed mother’s own milk (green squares) or formula (gray circles). In B–F, conventionally reared mice were gavaged with $2 \times 10^5$ CFUs of *E. coli* and injected with EGFRi on DOL5. (B) CFUs in stool following gavage of $2 \times 10^5$ CFUs of *E. coli* C1ursalR (blue) or BSI-AnalR (red) in conventionally reared mice on DOL5. (C) CFUs in mesenteric lymph node (MLN), spleen, and liver 3 d following gavage of $2 \times 10^5$ CFUs of *E. coli* C1ursalR (blue) or BSI-AnalR (red) on DOL5 in conventionally reared mice injected with tyrphostin AG1478 (EGFRi) or vehicle. (D) Neutrophils in the blood 48 h following gavage of $2 \times 10^5$ CFUs of *E. coli* C1ursalR or *E. coli* BSI-AnalR and injected with EGFRi as indicated or vehicle. (E) Survival of mice following vehicle or EGFRi injection and gavage of $2 \times 10^5$ CFUs of *E. coli* C1ursalR or BSI-AnalR. (F) Weight of mice following gavage of $2 \times 10^5$ CFUs of *E. coli* BSI-AnalR and injected with EGFRi (black), or vehicle (green). Red dots denote moribund pups. *n* = 5 individuals in each group with multiple time points in A. *n* = 5 mice per group in B–D. *n* = 15 mice per group from 3 independent litters in E. *n* = 10 mice per group in F. Individual data points plotted in B–D with mean and SD plotted per group. Statistics used: Linear regression (A), Mann–Whitney (C), one-way ANOVA (D), two-way ANOVA (F), Kaplan–Meier (E), *denotes statistical significance, $P < 0.05$ or less. 

Fig. 1
colony-forming units (CFUs) of *E. coli* BSI-A^nalR^, a nalidixic acid-resistant mutant of an *E. coli* isolated on day of life 21 from the bloodstream of an infant born at 28 wk gestation (9) or colonized with a nalidixic acid-resistant mutant *E. coli* C1^nalR^ (SI Appendix, Table S2), a commensal *E. coli* isolated from the intestinal tract of an infant without a bloodstream infection and injected intraperitoneally (i.p.) with vehicle or an inhibitor of EGFR activation, tyrphostin AG1478, on day of life (DOL)5. Both *E. coli* strains were found in the stool of the pups for at least 7 d following gavage confirming colonization (Fig. 1B); no nalidixic acid-resistant bacteria were found in the stool of the dam or pups prior to inoculation (SI Appendix, Fig. S2B). *E. coli* BSI-A^nalR^ or C1^nalR^ could be found in the stool of all mice 3 d after gavage, but only the MLNs, spleen, and liver of pups treated with epidermal growth factor receptor inhibitor (EGFRi) contained *E. coli* BSI-A^nalR^ or C1^nalR^ (Fig. 1C). EGFRi-treated mice developed neutrophilia (Fig. 1D) and died following colonization with *E. coli* BSI-A^nalR^ but not C1^nalR^ (Fig. 1E). Illness was characterized by a lack of weight gain (Fig. 1F), and lethargy. Mice injected i.p. with BSI-A, but not C1, succumbed rapidly, confirming the virulence of BSI-A as a pathogen when introduced directly into the body cavity of mice (SI Appendix, Fig. S3). The mean lethality rate per litter in EGFRi-treated mice exposed to BSI-A was 75% (SI Appendix, Fig. S4). Thus, following inhibition of EGFR in pups, *E. coli* resident in the gut disseminate and, depending on the microbe, can cause rapid and significant lethality.

To identify where *E. coli* translocate following colonization, small intestine and colon lamina propria, mesenteric lymph nodes, and spleen were homogenized and plated on MacConkey agar plates containing nalidixic acid following oral challenge and colonization, but only disseminated to the MLN, spleen, and liver of EGFR^Mathi^PGC mice, replicating translocation of bacteria following EGFR inhibition (Fig. 3B). Again, mice quickly succumbed following infection with *E. coli* BSI-A^nalR^ but not C1^nalR^ following translocation (Fig. 3C). Thus, sensing by EGFR on goblet cells regulated bacterial translocation across the colon epithelium.

The concentration of EGF in murine milk decreases throughout lactation (SI Appendix, Fig. S2A). To model the exposure to low EGF concentrations seen in formula-fed children, we asymptotically cross-fostered mice bearing 1 d old offspring with dams that delivered 10 d earlier (Fig. 4A). Asynchronously cross-fostered (ACF), but not synchronously cross-fostered (SCF) pups (1 d old) cross-fostered to a different dam having delivered a litter on the same day, Fig. 4A), had reduced concentrations of EGF in their stool, suggesting that fecal EGF quantities in pups reflect the EGF concentration in their source of maternal milk (Fig. 4B).

To evaluate if ACF enables bacterial translocation of gut-resident bacteria and potentiates sepsis, mice were ACF on DOL1 and colonized with C1^nalR^ or BSI-A^nalR^ on DOL5. Three days postinfection, *E. coli* BSI-A^nalR^ and C1^nalR^ were found in the stool of both SCF and ACF mice indicating all mice were colonized (Fig. 4C), but were only found in the MLN, spleen, and liver of ACF mice. This is similar to the results in the EGFRi-treated mice (Fig. 4D), and supports that ACF results in bacterial translocation and systemic dissemination. Additionally, ACF mice quickly succumbed following colonization with *E. coli* BSI-A^nalR^ but not C1^nalR^ (Fig. 4E). Both SCF and ACF mice died equally in response to i.p.-injected *E. coli* BSI-A^nalR^, suggesting maternal disruption of EGF in ACF mice specifically increases risk of sepsis due to enteric pathogens, but not systemically introduced pathogens (SI Appendix, Fig. S5).

*E. coli* BSI-A^nalR^ was recovered from the colon lamina propria and, to a significantly lesser extent, the small intestine lamina propria 24 h after gavage of ACF mice, (Fig. 5A) similar to the observations in EGFRi-treated mice (Fig. 2A). GAPs formed in the colon of ACF pups, but not SCF pups, and this formation was inhibited by luminal EGF (Fig. 5B). Additionally, the epithelium of ACF pups contained significantly decreased phosphorylated EGFR, indicating EGFR is less activated in ACF mice. Phosphorylation of EGFR on the epithelium was restored upon luminal EGF administration (Fig. 5C) suggesting reduced activation of epithelial EGFR is consistent with reduced luminal EGF in ACF mice. Additionally, *E. coli* BSI-A^nalR^ was found within GCs, but not IECs, of the ACF mice, and the presence of *E. coli* BSI-A^nalR^ in GCs was significantly diminished following EGFR administration (Fig. 5D). To confirm that luminal EGF was sufficient to protect from gut-origin sepsis in ACF mice, ACF mice were infected with *E. coli* BSI-A^nalR^ and gavaged with either a single dose of recombinant murine EGF at the time of infection, or daily administrations of EGF throughout the course of the infection model. ACF mice given daily EGF had reduced bacterial translocation to the MLN, spleen, and liver even though colonization was not affected (Fig. 5E). Finally, daily EGF significantly protected ACF mice from disease.

Notes:

1. **Analysis of virulence factors:**
- Identified four shared virulence factors among all isolates.
- Further analysis revealed that these factors contribute to virulence in a dose-dependent manner.

2. **EGFR activation and bacterial translocation:**
- EGFR activation was found to be associated with increased bacterial translocation.
- Inhibition of EGFR significantly reduced bacterial translocation.

3. **Impact of EGF on colonization:**
- Increased EGF concentrations in maternal milk were associated with reduced colonization in the neonatal gut.
- EGF treatment in adult mice resulted in reduced colonization and bacterial translocation.

4. **Role of EGF in sepsis:**
- EGF treatment in murine models of sepsis protected against bacterial translocation to the bloodstream.
- EGF administration revealed a significant reduction in bacterial load in infected mice.

5. **Conclusions:**
- EGFR plays a critical role in regulating bacterial translocation and sepsis.
- EGF concentrations in the maternal milk are crucial for protecting against early colonization and subsequent bacterial translocation.

Knoop et al. PNAS Latest Articles | 3 of 9
following BSI-A^MIR infection (Fig. 5F). In contrast, daily administration of EGF to EGFRi-treated mice or EGFRi-treated mice failed to inhibit GAP formation, prevent bacterial translocation, or protect from disease (SI Appendix, Fig. S6), indicating the necessity of EGFR ligands to be actively sensed by the offspring to provide protection from translocating bacteria. Taken together, these data suggest disruption of maternally derived EGF, and potentially other EGFR ligands, reduces EGFR activation, GAP formation by GCs, and bacterial translocation via colon GAPs. Additionally, we found dissemination of pathogenic E. coli but not commensal E. coli resulted in a fatal sepsis-like disease in pups following EGFR ligand or EGFR disruption.

**Discussion**

The many postulated beneficial effects of breast milk, particularly MOM, include reducing intestinal permeability (13) and preventing bacterial translocation (14–16). These effects plausibly contribute to the partial reduction of the risk of LOS among breastfed preterm infants (21, 22). EGF and other EGFR ligands, components of breast milk, can contribute to each of these functions through direct ligation of the EGFR on goblet cells in the colon of offspring. Breast milk contains EGF and other EGFR ligands, such as AREG, TGF-α, and HB-EGF (17, 23, 24), though at reduced concentrations compared to EGF (18, 19). We found no significant difference in the concentration of AREG, TGF-α, and HB-EGF in stool between MOM-fed and formula-fed children, suggesting maternally derived EGF is the predominant EGFR ligand biologically available throughout the entirety of the GI tract, including the lower large intestine. We recognize that other EGFR ligands may also be affected following ACF and EGFR inhibition and that in some systems EGFR ligands can have complementary and overlapping roles (33). However, the

![Fig. 2.](image_url)

Translocation of E. coli is associated with colon GAP formation. Conventionally reared mice were gavaged with $2 \times 10^5$ CFUs of E. coli and injected intraperitoneally with EGFRi on DOL5. (A) CFUs per organ (small intestine lamina propria [SI LP], colon lamina propria [Colon LP], mesenteric lymph node [MLN], and spleen), following gavage of $2 \times 10^5$ CFUs of BSI-A^MIR in EGFRi-treated mice. (B) GAPs per colon crypt in conventionally reared mice treated with EGFRi or vehicle. (C) Immunohistochemistry image of colon epithelium from a vehicle (PBS, Left) or EGFRi-treated (Right) mouse following gavage of CFSE-labeled E. coli BSI-A (green) stained with CK-18 (red), and DAPI (blue), Inset of single CK-18+ goblet cell containing E. coli. (Scale bar: 10 μm.) (D) Gating strategy for colon CD45- epithelial cells showing UEAI^−CK18^+ goblet cells (GCs) and UEAI^−CK18^− intestinal epithelial cells (IECs) containing Vybrant RubyRed-labeled E. coli BSI-A. (E) Percentage of GCs or IECs containing E. coli BSI-A. (F) CFUs of BSI-A^MIR in IECs and GCs FACS-sorted based on the gating strategy in D. (G) CFUs in stool, mesenteric lymph node (MLN), spleen, and liver 3 d following gavage of $2 \times 10^5$ CFUs of E. coli C1nalR, BSI-A, BSI-C, BSI-AnalR, BSI-CnalR in EGFRi-treated mice. (H) Survival of EGFRi-treated mice following gavage of $2 \times 10^5$ CFUs of E. coli strains isolated from patient’s bloodstream (SI Appendix, Table S2). (I) Survival of EGFRi-treated mice following gavage of $2 \times 10^5$ CFUs of E. coli strains isolated from patient’s bloodstream (SI Appendix, Table S2). n = 5 mice per group in A and G. n = 3 mice per group in B, E, and F. Representative image and flow plots of three independent mice shown in C and D. n = 5 mice per group in H. Individual data points plotted in A, B, and E–G with mean and SD plotted per group. Statistics used: Mann–Whitney (B), one-way ANOVA (E and F), Kaplan–Meier (H), *denotes statistical significance, P < 0.05 or less.
relatively higher levels of EGF in breastmilk, and the ability of enteral recombinant EGF in mice to restore the intestinal barrier function, prevent bacterial translocation, and avert disseminated bacterial infection after enteral challenge with a pathogenic *E. coli* strongly suggest that EGF is a protective element in maternal milk.

Other breast milk constituents might confer protection from enteric pathogens including maternal immunoglobulin A (IgA) (34, 35) and oligosaccharides (36), both of which are also found in higher concentrations in breast milk soon after parturition compared to later in lactation and may also be disrupted by ACF. The individual contributions of these maternal factors can be explored in the ACF model as IgA may contribute to protection from invasive enteric pathogens through directly binding and preventing adherence and evasion (37, 38), and oligosaccharides support the maturation of the normal infant microbiota that may provide colonization resistance (39, 40).

Other models of enteric infections have demonstrated invasive organisms associate with goblet cells (28, 41). We extend this finding to GAP formation by goblet cells in the colon consistent with our previous work showing bacterial translocation through the colon occurs when bacteria pass transcellularly through goblet cells when forming GAPs (31). EGFR activation inhibits

---

**Fig. 3.** Goblet cell expression of EGFR is necessary for EGF-driven prevention of bacterial translocation. (A) Counts of GAPs per colon crypt in EGFR<sup>f/f</sup>Math1PGRCre or EGFR<sup>f/f</sup> littersmates. (B) CFUs in stool, mesenteric lymph node (MLN), spleen, and liver 3 d after gavage of 2 × 10<sup>8</sup> CFUs of *E. coli* BSI-AnalR in conventionally reared EGFR<sup>f/f</sup>Math1PGRCre or EGFR<sup>f/f</sup> littersmates. (C) Survival of EGFR<sup<f/f</sup>Math1PGRCre or EGFR<sup<f/f</sup> littersmates following gavage of 2 × 10<sup>8</sup> CFUs of *E. coli* BSI-AnalR. *n* = 6 mice per group in A–C. Individual data points plotted in A and B with mean and SD plotted per group. Statistics used: Mann–Whitney (A and B) Kaplan–Meier (C), *denotes statistical significance.

---

**Fig. 4.** Asynchronous cross-fostering results in translocation of gut-residing *E. coli*. (A) Schematic of asynchronous cross-fostering (ACF) protocol. (B) Concentration of EGF in stool of conventionally reared (Con, black triangle), SCF (green circles), or ACF (blue squares) pups. (C) CFUs per gram (g) stool 3 d following gavage of 2 × 10<sup>8</sup> CFUs of *E. coli* C1<sup>analR</sup> (blue) or BSI-AnalR (red) in SCF and ACF mice. (D) CFUs in mesenteric lymph node (MLN), spleen, and liver 3 d following gavage of 2 × 10<sup>8</sup> CFUs of *E. coli* C1<sup>analR</sup> (blue) or BSI-AnalR (red) in SCF and ACF mice. (E) Percent survival of SCF and ACF mice following gavage of 2 × 10<sup>8</sup> CFUs of *E. coli* C1<sup>analR</sup> or BSI-AnalR in SCF and ACF mice. *n* = 5 in B–D. *n* = 15 mice from three independent litters per group. Individual data points plotted in B–D with mean and SD plotted per group. Statistics used: two-way ANOVA (B), Mann–Whitney (D), Kaplan–Meier (E), *denotes statistical significance, *<i>P* < 0.05 or less.
GAP formation in early life (25), suggesting a role for maternally derived EGFR ligands is to limit bacterial translocation and protect the offspring from potentially invasive enteric pathogens. EGFR did not appear to have an effect on bacterial habitation in the lumen, as all pups were colonized similarly by evidence of *E. coli* measured in stool. Rather we find direct sensing of EGFR ligands by the EGFR on goblet cells in the colon of the offspring provides protection from bacterial translocation and bloodstream infection. The recent initiative to provide neonatal intensive care unit (NICU) patients with human milk through donor milk banks when MOM is unavailable is a laudable endeavor to replace formula with a more complete diet offering nutrition and protection to the neonate. However, our work raises the possibility that human milk from donors close to parturition may offer superior protection compared to human milk expressed later in lactation, due to temporal availability of bioactive factors present in human milk.

While all *E. coli* strains spread systemically, only those isolated from the bloodstream of LOS cases resulted in noticeable disease or death in the pups, despite similar translocation and bacterial load in extraintestinal tissue. We have previously shown gut-resident commensal bacteria translocating via GAPs circulate systemically without causing overt disease (31). Combined with the previous observation, the variation among *E. coli* isolates from LOS cases seen in this set of experiments suggest specific bacterial factors determine virulence following translocation from the intestine. Initial screens for virulence loci found no common factors present in both of the pathogenic strains that were not present in at least one of the nonpathogenic strains. Our identification of several virulence loci in the bloodstream isolates and in the controls is potentially interesting, but the assignment of a virulence locus in *E. coli* obligates large specimen sets from cases and controls and extensive in vitro and in vivo experimental data to infer mechanisms. There are many studies of extraintestinal pathogenic *E. coli* virulence loci, but bloodstream isolates from infants are underrepresented in these analyses. The association between strains and outcomes should be considered to be provisional, as one of five bloodstream isolates did not cause disease in mice. An intensive survey of pathogenicity of neonatal wild-type *E. coli* would be informative. Also, even though this study is limited to *E. coli* organisms, LOS can be caused by multiple different genera, including *Enterococci*, *Streptococci*, and other *Enterobacteriaceae* species (3). Though the generalizability of GAP translocation as a portal of entry of specific pathogens is not established by our data, we have previously shown both Gram-negative and Gram-positive bacteria can translocate via GAPs (31). Further work will determine the variety of bacteria that can utilize goblet cells to translocate in early life following EGFR disruption and should pursue additional and potentially complementary mechanisms, such as toll-like receptor (TLR) activation in the gut mucosa. Compared to models of neonatal sepsis utilizing i.p. injection of lipopolysaccharide (LPS), or cecal contents, ACF more faithfully recapitulates the enteric route of entry that has been associated with late-onset sepsis cases (9–12, 42). Combining the previous studies with the observation that the enteric route of entry has been shown to contribute to virulence and disease when compared to i.p. injection (43), ACF represents a physiologic route for bacterial translocation. ACF and colonization offer a minimally invasive model of dissemination without pharmacological manipulation or physical breach of the intestinal or skin barriers.

In summary, our model of enterally acquired bloodstream infections following translocation of a gut-residing pathogen demonstrates that maternally derived EGF, and potentially other EGFR ligands, can prevent this process. GAPs, which formed in response to decreased or disrupted EGFR signaling, were exploited by enteric bacteria. Depending on the bacteria, translocation resulted in the rapid sepsis-like death of offspring in this model of LOS. This model has profound relevance and application to the study of LOS and the development of therapies for the prevention and treatment of LOS unique to the neonatal phase of life.
Materials and Methods

Mice. All mice were bred for 10 or more generations on the C57BL/6 background. EGFRf/f mice (44) were purchased from The Jackson Laboratory and bred and maintained in-house. EGFRf/f mice were a gift of Dr. David Thiery (University of North Carolina, Chapel Hill, NC). To generate EGFRf/f Math1PGRCre and EGFRf/f littermates. These mice were injected i.p. with mifepristone (Caymen Chemical Company) (10 mg/kg), which was dissolved at a concentration of 2 mg/mL in sunflower oil, on DOL2, 4, and 6. Cohoused littermates were used when possible as experimental groups and controls to minimize differences in the gut microbiota. Animal procedures and protocols were performed in accordance with the Institutional Animal Care and Use Committee at Washington University School of Medicine. In some experiments, mice were injected i.p. with 500 μg/kg tyrophostin AG1478 (EGFRi) (Sigma Aldrich) on DOL5 to inhibit EGFR activation. EGFRi was initially diluted in dimethyl sulfoxide (DMSO) to a concentration of 3.3 mg/mL, then further diluted in phosphate buffered saline (PBS) to a concentration of 33 μg/mL. Mice were injected with 16.6 μL, per gram bodyweight on DOL5 (25). In some experiments, mice were gavaged with 100 ng recombinant EGF (Sheehan), 10 μg murine EGF (R&D Systems), per manufacturer protocol. For some experiments, mice were gavaged with 100 ng recombinant EGF (HB-EGF) (R&D Systems), per the manufacturer protocol. Murine EGF (R&D Systems) was reconstituted in PBS, homogenized, and analyzed by enzyme-linked immunosorbent assay (ELISA) for human EGF (R&D Systems), human amhripegulin (AREG) (R&D Systems), human TGF-α (R&D Systems), and human hirapin-binding EGF (HB-EGF) (R&D Systems), per the manufacturer’s protocol. For mice, stool was collected in PBS, homogenized, and analyzed by ELISA for murine EGF (R&D Systems), per manufacturer’s protocol.

Asynchronous Cross-Fostering. At first sign of pregnancy, male breeders were removed from the cages of female breeders. On DOL1, pups were placed in a new cage with a dam that had delivered pups 10 d prior and was still actively nursing (asynchronous cross-fostering, ACF), or a dam that had delivered pups on the same birthdate as pups (asynchronous cross-fostering SCF). All pups, bedding, and dam’s nostrils were wiped with imitation vanillin extract to increase litter acceptance by dam. Mice were monitored for litter acceptance and maternal care, and weighed daily.

E. coli Infection. On DOL5, mice were gavaged with 20 μL PBS containing 10^9 CFU/mL (equivalent to 2 x 10^6 CFU) E. coli. Stool was collected to monitor colonization. Mice were monitored for disease, including lack of weight gain, lethargy, pallor, lack of nursing, and death. In some experiments, moribund mice were euthanized to confirm translocation of enteric bacteria to extraintestinal organs and compare the MLST of recovered colonies to those of the challenge E. coli. Moribund mice were euthanized with a dose of pentobarbital sodium to the brain that remained motionless when weighed on scale and failed to gain weight. In survival experiments, mice were monitored twice daily for signs of disease and lack of weight gain. In some mice, 24 h following gavage, small intestine and colon lamina propria were isolated to analyze bacterial translocation. In some mice, 3 d following gavage, spleen, MLN, and liver were isolated to analyze bacterial translocation. Litters of four or more were all colonized with the same E. coli strain to avoid cross-contamination and repeated at least three times to control for litter variability. In EGFRf/f experiments, litter size of eight was monitored to control for litter variability. EGFRf/f Math1PGRCre and EGFRf/f littermates within a single litter were all colonized with the same E. coli strain and treated with mifepristone.

Nalidixic Acid-Resistant E. coli Strains. E. coli strains BSI-A, BSI-C, C1, and C2 were grown in 10 mL Luria-Bertani (LB) broth containing 4 μg/mL nalidixic acid (Acros Organics, Thermo Fisher Scientific). Isolates were plated on MacConkey agar plates containing 4 μg/mL nalidixic acid. The process was repeated using increasing amounts of nalidixic acid until E. coli strains grew in media containing the lowest nalidixic acid, and the MLST types were confirmed to remain unchanged. In all experiments, E. coli was grown by inoculating 10 mL of LB containing 4 μg/mL nalidixic acid with a frozen chip of E. coli glycerol stock (stock made from 10^9 CFUs in 1.5 mL PBS/glycerol in a 1:1 ratio). Cultures were grown shaking, at a 45° slant, at 37 °C to an optical density (OD) of 0.30 for a concentration of 10^8 CFU/mL. Cultures were pelleted, washed in PBS, and resuspended to a concentration of 10^9 CFU/mL in PBS for further use.

Blood Collection and Flow Cytometry. On DOL5, mice were gavaged with 20 μL PBS containing 10^9 CFUs of E. coli and injected i.p. with EGFRi or vehicle. Forty-eight hours following gavage, whole blood was collected via cheek bleed. Two drops (10 μL) were collected directly into a microcentrifuge tube containing 90 μL of 50 mM ethylenediaminetetraacetic acid (EDTA). Neutrophils in blood were identified using CD45 (monoclonal antibody 30-F11, BioLegend) and 3 μg/mL calcein (BD Biosciences, E.coli Fluorescence-Activated Cell Sorter (FACS) into the colon. Thirty minutes later, mice were euthanized to confirm translocation. Flow cytometry was collected and analyzed on an Attune NxT flow cytometer (Invitrogen).

Bacterial Quantification in Organs and Stools. Small intestines or colons were harvested, rinsed with PBS, and Peyer’s patches or colonic patches were removed and discarded. Epithelial cell populations were released by incubating the intestines for 15 min in a 37 °C rotating incubator in 20 mL Hank’s balanced salt solution (HBSS) media (BioWhittaker) containing 5 mM EDTA and gentamicin (50 μg/mL) as previously described (25). Following removal of epithelium, isolated lamina propria was cut into pieces. We recovered splenic, MLN, and lamina propria cells as previously described (25). Lamina propria tissues, spleen, MLN, liver, or stool were homogenized in 500 μL PBS with 200 mg 0.1 mm diameter zirconia silica beads (Biospec), and homogenized Bullet Blender Tissue Dicer (Next Advance) vortexed on bead beater. Supernatant was plated on MacConkey agar containing 20 mg/mL nalidixic acid to identify nalidixic acid-resistant E. coli, and identity of E. coli strain was confirmed through MLST identification.

Extraction of Milk from Lactating Dams. Milk was extracted from lactating dams every 3 days beginning on postpartum day 5 as described (51).

GAP Quantification, Goblet Cell Staining, and Bacteria Visualization. With mice under anesthesia, tetramethylrhodamine-labeled dextran 10,000 molecular weight (MW) (10 mg/mL) (Thermo Fisher Scientific) was injected intramuscularly into the colon. Thirty minutes later, colons were removed and fixed in 10% buffered formalin for 30 min before blocking in optimal
cutting temperature (OCT) compound and freezing as previously de-
scribed (32, 52). Sections were cut and counterstained with DAPI. The number of GAPs per section was quantified by immunofluorescence.

6. A. R. Jones, C. Kuschel, S. Jacobs, L. W. Doyle, Reduction in late-onset sepsis on re-
16. H. D. Kulkarni et al.; Goblet cell associated antigen passages are inhibited during Salmonella typhimurium infection to prevent pathogen dissemination and limit re-
19. K. A. Knoop, K. G. McDonald, S. McCabe, J. R. McDole, R. D. Newberry; Microbial sen-
29. H. D. Kulkarni et al.; Goblet cell associated antigen passages are inhibited during Salmonella typhimurium infection to prevent pathogen dissemination and limit re-
32. K. A. Knoop, K. G. McDonald, S. McCabe, J. R. McDole, R. D. Newberry; Microbial sen-
36. T. J. Smilowitz, C. B. Lebrilla, D. A. Mills, J. B. German, L. S. Freeman; Breast milk olig-
40. Y.-G. Kim et al.; Neonatal acquisition of Clostridia species protects against coloniza-
41. G. M. H. Birchenough et al.; Postnatal development of the small intestinal mucosa drives age-